Ivan Borrello, MD
Medical Oncology · Tampa, FLNPI 1992761050
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $235,609 of the $336,383 with a category attached, or 70.0%. 32 manufacturers reported payments, led by Gamida Cell Inc. at 54.3% of the total. Among medical oncology clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 202 payments — averaging $1665.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gamida Cell Inc.$183K
- Sanofi$86K
- Regeneron Healthcare Solutions, Inc.$21K
- Mckesson Sourcing Services, Inc.$19K
- Bristol Myers Squibb$11K
- Astrazeneca UK Limited$5K
- plus $13K from 26 others
Across 26 payments — averaging $8773.56 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bristol Myers Squibb$87K
- E.r. Squibb & Sons, L.L.C.$71K
- Gilead$38K
- Beigene, Ltd.$19K
- Novartis$13K
- Pfizer$900
What the payments were for
- Consulting fees$235,60970%
- Speaking & faculty fees$76,81623%
- Travel & lodging$13,0874%
- Food & beverage$10,8583%
- Education$120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gamida Cell Inc. | 8 | $182,619 |
| Sanofi | 49 | $85,706 |
| Regeneron Healthcare Solutions, Inc. | 12 | $20,753 |
| Mckesson Sourcing Services, Inc. | 30 | $18,994 |
| Bristol Myers Squibb | 17 | $10,785 |
| Astrazeneca UK Limited | 2 | $4,800 |
| Adaptive Biotechnologies Corporation | 10 | $4,659 |
| AstraZeneca | 7 | $2,514 |
| Genetix Biotherapeutics Inc | 17 | $1,326 |
| Johnson & Johnson(2 entities) | 9 | $973 |
| Gilead(2 entities) | 3 | $388 |
| Seagen Inc. | 3 | $320 |
| Genmab U.S., Inc. | 3 | $316 |
| Janssen Scientific Affairs, LLC | 3 | $265 |
| Karyopharm Therapeutics Inc. | 4 | $261 |
| Sirtex Medical Inc | 2 | $209 |
| Regeneron | 1 | $143 |
| ADC Therapeutics America, Inc. | 1 | $121 |
| TG Therapeutics, Inc. | 1 | $120 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $120 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $120 |
| Pfizer | 1 | $119 |
| Eisai Inc. | 2 | $114 |
| Daiichi Sankyo Inc. | 1 | $105 |
| Novartis | 5 | $104 |
| Incyte Corporation | 1 | $100 |
| Legend Biotech USA Inc. | 2 | $85 |
| Pierre Fabre Pharmaceuticals, Inc. | 1 | $72 |
| Amgen | 1 | $66 |
| E.r. Squibb & Sons, L.L.C. | 1 | $51 |
| Menarini Silicon Biosystems, Inc. | 1 | $30 |
| Geron Corporation | 1 | $27 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$336,383 in reported general payments places this provider in the 95th percentile of 507 medical oncology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lenalidomide | 39 | $545,210 |
| Darzalex FasproDaratumumab-Hyaluronidase-Fihj | 20 | $325,748 |
| RevlimidLenalidomide | 23 | $317,044 |
| ImbruvicaIbrutinib | 11 | $175,292 |
| VenclextaVenetoclax | 14 | $90,293 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 13 | $28,095 |
| Ondansetron Hcl | 19 | $3,869 |
| Entecavir | 18 | $1,402 |
| Acyclovir | 51 | $544 |
| Dexamethasone | 25 | $275 |
| Prochlorperazine Maleate | 12 | $160 |
| Oxycodone Hcl | 14 | $71 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 11 | $32 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $10,785 | $317,04423 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $120 | $175,29211 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid | $120 | $28,09513 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 507 medical oncology providers in Florida.
Other medical oncology in Tampa
- Eduardo SotomayorTampa$362K
- Kenneth ShainTampa$341K
- Alberto ChiapporiTampa$325K
- Jingsong ZhangTampa$220K
- Sameh GaballaTampa$214K
- Adil DaudTampa$204K
- Jeffrey WeberTampa$193K
- Mayer FishmanTampa$193K
- Jonathan StrosbergTampa$148K
- Boris NaraevTampa$144K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.